In virtually all persons with amyotrophic lateral sclerosis (ALS) and in up to half of all cases of Alzheimer’s disease (AD) and frontotemporal dementia, a protein called TDP-43 is lost from its normal location in the nucleus of the cell. In turn, this triggers the loss of stathmin-2, a protein crucial to regeneration of neurons and the maintenance of their connections to muscle fibers, essential to contraction and movement.
Writing in the journal Science, a team of scientists, demonstrate that stathmin-2 loss can be rescued using designer DNA drugs that restore normal processing of protein-encoding RNA.
“With mouse models we engineered to misprocess their stathmin-2 encoding RNAs, like in these human diseases, we show that administration of one of these designer DNA drugs into the fluid that surrounds the brain and spinal cord restores normal stathmin-2 levels throughout the nervous system,” the senior author said.
Several designer DNA drugs are currently in clinical trials for multiple diseases. One such drug has been approved to treat a childhood neurodegenerative disease called spinal muscular atrophy.
The new study builds upon ongoing research regarding the role and loss of TDP-43, a protein associated with ALS, AD and other neurodegenerative disorders. In ALS, TDP-43 loss impacts the motor neurons that innervate and trigger contraction of skeletal muscles, causing them to degenerate, eventually resulting in paralysis.
“In almost all of instances of ALS, there is aggregation of TDP-43, a protein that functions in maturation of the RNA intermediates that encode many proteins. Reduced TDP-43 activity causes misassembly of the RNA-encoding stathmin-2, a protein required for maintenance of the connection of motor neurons to muscle,” said the senior author.
“Without stathmin-2, motor neurons disconnect from muscle, driving paralysis that is characteristic of ALS. What we have now found is that we can mimic TDP-43 function with a designer DNA drug, thereby restoring correct stathmin-2 RNA and protein level in the mammalian nervous system.”
Specifically, the researchers edited genes in mice to contain human STMN2 gene sequences and then injected antisense oligonucleotides — small bits of DNA or RNA that can bind to specific RNA molecules, blocking their ability to make a protein or changing how their final RNAs are assembled — into cerebral spinal fluid. The injections corrected STMN2 pre-mRNA misprocessing and restored stathmin-2 protein expression fully independent of TDP-43 function.
“Our findings lay the foundation for a clinical trial to delay paralysis in ALS by maintaining stathmin-2 protein levels in patients using our designer DNA drug,” the author said.
https://www.science.org/doi/10.1126/science.abq5622
Correcting TDP-43 proteinopathies
- 494 views
- Added
Latest News
Citrullination is a key pla…
By newseditor
Posted 14 Sep
Senolytic therapy clinical…
By newseditor
Posted 14 Sep
Genetic tools probe microbi…
By newseditor
Posted 13 Sep
A secret passage for mutant…
By newseditor
Posted 11 Sep
Specialized T cells in the…
By newseditor
Posted 10 Sep
Other Top Stories
Why young bones repair fractures faster than the old ones?
Read more
Using graphene to detect ALS, other neurodegenerative diseases
Read more
A mechanistic approach to neuroblastoma prognosis and risk
Read more
Cellular energy sensor linked to the progression of chronic kidney…
Read more
A tool for capturing RNA-protein interactions!
Read more
Protocols
Genetic manipulation of Pat…
By newseditor
Posted 13 Sep
Single-nucleus RNA sequenci…
By newseditor
Posted 08 Sep
Engineering RNA export for…
By newseditor
Posted 25 Aug
ATP production from electri…
By newseditor
Posted 21 Aug
Labeling PIEZO2 activity in…
By newseditor
Posted 20 Aug
Publications
Timing of lifespan influenc…
By newseditor
Posted 16 Sep
Transformer-based biomarker…
By newseditor
Posted 16 Sep
Somatic variants of MAP3K3…
By newseditor
Posted 16 Sep
The NLRP3 inflammasome and…
By newseditor
Posted 15 Sep
Targeting the metabolism of…
By newseditor
Posted 15 Sep
Presentations
Hydrogels in Drug Delivery
By newseditor
Posted 12 Apr
Lipids
By newseditor
Posted 31 Dec
Cell biology of carbohydrat…
By newseditor
Posted 29 Nov
RNA interference (RNAi)
By newseditor
Posted 23 Oct
RNA structure and functions
By newseditor
Posted 19 Oct
Posters
A chemical biology/modular…
By newseditor
Posted 22 Aug
Single-molecule covalent ma…
By newseditor
Posted 04 Jul
ASCO-2020-HEALTH SERVICES R…
By newseditor
Posted 23 Mar
ASCO-2020-HEAD AND NECK CANCER
By newseditor
Posted 23 Mar
ASCO-2020-GENITOURINARY CAN…
By newseditor
Posted 23 Mar